Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2025-02-03
DOI
https://doi.org/10.3389/fimmu.2025.1512189
Citations
9
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
13.24

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study

Finn Thorup Sellebjerg, Anita Chudecka, Andreas Kloetgen, Nicola De Stefano et al.
9 citations
Frontiers in Immunology
Multiple Sclerosis Research Studies
13.24
article

Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study

Finn Thorup Sellebjerg, Anita Chudecka, Andreas Kloetgen, Nicola De Stefano, Patrick Vermersch, Xavier Montalbán, Letizia Leocani, Klaus Schmierer, Suzanne Hodgkinson, Lidia A. Gardner, Frederik Barkhof, Andrew T. Chan, Tobias J Derfuss, Alexandre Prat, Anat Achiron, Dongdong Lin, Heinz Wiendl, Hulin Jin
article en
9 citations

Abstract

No abstract available for this paper.
Frontiers in ImmunologyVol. 16
University of Siena (IT), University of Bern (CH), University of Copenhagen (DK), Vita-Salute San Raffaele University (IT), Inserm (FR), Tel Aviv University (IL), Merck KGaA, Darmstadt (Germany) (DE), Queen Mary University of London (GB), University of Münster (DE), Barts Health NHS Trust (GB), Université de Lille (FR), Sheba Medical Center (IL), Liverpool Hospital (AU), University Hospital of Bern (CH), Royal London Hospital (GB), University Hospital of Basel (CH), Copenhagen University Hospital (DK), Rigshospitalet (DK), Centre Hospitalier Universitaire de Lille (FR), UNSW Sydney (AU), Ono Pharmaceutical (United States) (US), Casa di Cura Columbus (IT), Research & Development Institute (US), Ingham Institute (AU), National Hospital for Neurology and Neurosurgery (GB), Amsterdam University Medical Centers (NL), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Centre d'Esclerosi Múltiple de Catalunya (ES), University College London (GB), Université de Montréal (CA), Vrije Universiteit Amsterdam (NL), Cytel (United States) (US)
Bristol-Myers Squibb, Sanofi, Biogen, Teva Pharmaceutical Industries, Alexion Pharmaceuticals, Celgene, CSL Behring, McGill University, Merck KGaA, McGill University Health Centre, Prothena, Fresenius Medical Care North America, University of Alberta, National Institute for Health and Care Research, European Commission, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Technische Universität Dresden, Westfälische Wilhelms-Universität Münster, Rheinische Friedrich-Wilhelms-Universität Bonn, University College London Hospitals NHS Foundation Trust, Regione Toscana, MedDay Pharmaceuticals, EMD Serono, Medical Research Council
Good health and well-being
Openalex Percentile: Top 1%
Multiple Sclerosis Research Studies
13.24
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.